Spots Global Cancer Trial Database for Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization

Official Title: A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization

Study ID: NCT04065737

Conditions

Oral Cavity Cancer

Mouth Neoplasm

Precancerous Conditions

Interventions

Sintilimab

Study Description

Brief Summary: This is a non-randomized, phase II, open-label study. The goal of this clinical research study is to investigate how well sintilimab works in preventing high-risk oral premalignant lesions cancerization.

Detailed Description: this study is a non-randomized, phase II, open-label study. Phase II clinical trials test the safety and effectiveness of an investigational drug or combination of drugs to learn whether it works in preventing or treating a disease. the purpose of this study is to evaluate the effectiveness of sintilimab in preventing the onset of oral cancer in patients with high-risk oral premalignant lesions, who had oral cancer at least once before.